Vásquez-Awad D, Neyro JL

Language: Spanish
References: 9
Page:
PDF size: 78.19 Kb.

Text Extraction

No abstract.

REFERENCES

1. Gordon J, Rubinow D, Eisenlohr-Moul T, et al. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition – A Ransomized Clinical Trial (published on line January 10 2018). JAMA Psychiatry.doi

2. Thomas JL, Jones GN, Scarinci IC, et al. The Center for Epidemiologic Studies-Depression. The utility of the CES-D as a depression screening measure among low-income women attending primary care clinics. Int J Psychiatry Med. 2001;31(1):25-40.

3. Position Statement. The 2017 hormone therapy position statemet of the North American Menopause Society. Menopause2017;24(7)

4. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of clinical endocrinologists and American College of Endocrinology position statement on Menopause-2017 update. Endocr Pract. 2017 Jul; 23(7):869-880.

5. Vásquez-Awad D, Palacios S. Menopausia: una visión clínica. Bogotá: Kimpres, 2016.

6. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climateric 2016;19:109-50.

7. Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and Alzheimer disease: a prospective cohort study. Neurology 2017;88:1062-1068.

8. Neyro JL. La terapia hormonal de la menopausia protege (también) del Alzheimer. En https://www.neyro.com/2017/03/29/la-terapia-hormonal-de-la-menopausia-protege-tambien-del-alzheimer/ Último acceso 15.01.2018.

9. Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016 Mar 31; 374(13):1221-31. doi: 10.1056/NEJMoa1505241